The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.
H. Isayama
No relevant relationships to disclose
Y. Nakai
No relevant relationships to disclose
T. Sasaki
No relevant relationships to disclose
N. Sasahira
No relevant relationships to disclose
K. Hirano
No relevant relationships to disclose
T. Tsujino
No relevant relationships to disclose
M. Tada
No relevant relationships to disclose
M. Omata
No relevant relationships to disclose
K. Koike
No relevant relationships to disclose